Bio-Rad Laboratories, a life science research and clinical diagnostic products specialist, has been in the news due to various financial activities. Brokerages have given the company an average
Moderate Buy rating. Major holdings by
Brown Advisory Inc and other major Entities including
Mitsubishi UFJ Asset Management have been announced. The company has also faced recent
stock losses and documented sales of company shares by entities such as
Envestnet Portfolio Solutions Inc. Q1 2024 reported
earnings beat EPS, yet missed revenue targets. Records indicate a strong
balance sheet, but also identify concerns about
competition and softer performance in the BioPharma sector. A promising
partnership with Oncocyte caused a notable stock rally. However, doubt has been raised over the company’s revenues. Further moves in the market include a share purchase by
Yousif Capital Management LLC and the company's increased financial flexibility due to a new
credit facility. A $500M
share repurchase program has been announced. Notwithstanding, both Q3 earnings and revenues missed estimates. The executive Vice President,
Andrew Last has announced retirement plans.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jun 2018 02:34:36 GMT to Thu, 23 May 2024 18:03:38 GMT -
Rating -3
- Innovation 0
- Information 5
